SHERLOCK 3CG™ Diamond Tip Confirmation System

Atrial Flutter Clinical Trial

— MODUS II  

Official title:

A Single-Arm Prospective, Multi-Centered Study to Assess the SHERLOCK 3CG™ Diamond Tip Confirmation System

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03288766
• Other study ID #: BAS-14-003
• Status: Terminated
• Start date: April 19, 2018
• Est. completion date: June 15, 2021

Study information

• Verified date: January 2021
• Source: C. R. Bard
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study is a single-arm, prospective, multi-center study to assess clinical performance of the SHERLOCK 3CG™ Diamond Tip Confirmation System (TCS) with MODUS II software for confirming correct tip position of peripherally inserted central catheters (PICCs) in adult subjects with altered cardiac rhythm.

Description:

This study is intended to confirm the accuracy of the SHERLOCK 3CG™ Diamond TCS with the addition of MODUS II (SLM2) software to eliminate the need for post-procedural chest x-ray (CXR) in adult subjects with cardiac abnormalities that alter presentation of the P-wave. Atrial fibrillation will be the primary target while data on pacemaker driven rhythms and other arrhythmia types will also be collected to explore overall performance.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 232
• Est. completion date: June 15, 2021
• Est. primary completion date: June 15, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 21 Years and older

Eligibility

Inclusion Criteria:

• Male or female, = 21 years of age with altered cardiac rhythm (no recognizable P-wave on standard ECG) with diagnosis of specific arrhythmia type or identification of pacemaker driven rhythms as defined below:

1. Atrial fibrillation with history of diagnosis per 12-lead ECG in medical record or diagnosed via bedside telemetry by study team RN at assessment, or

2. All other arrhythmias (including but not limited to atrial flutter, PAC, PVC, PJC, tachycardia, AV Block, BB Block) with history of diagnosis per 12-lead ECG in medical record or diagnosed via bedside telemetry by cardiac unit RN at assessment, or retrospectively by site cardiologist, or

3. Pacemaker driven rhythm with temporary or permanent pacemaker device in place;

• Subject requires PICC placement as part of standard of care;

• Subject or Legally Authorized Representative (LAR) has signed an Informed Consent Form (ICF).

Exclusion Criteria:

• Subject has a contraindication to PICC placement as listed in the Instructions for Use (IFU) to include:

1. The presence of bacteremia or septicemia (known or suspected),

2. The patient's body size is insufficient to accommodate the size of the implanted device,

3. The patient is known or is suspected to be allergic to materials contained in the device,

4. Past irradiation of prospective insertion site,

5. Previous episodes of venous thrombosis or vascular surgical procedures at the prospective placement site,

6. Local tissue factors will prevent proper device stabilization and/or access;

• Subjects who previously had a PICC in place and require a PICC exchange;

• Subject has presence of active resting tremor (i.e. Parkinson's, Multiple Sclerosis, etc.) deemed by Investigator to have potential impact on procedure accuracy;

• Subjects who are pregnant or think they may be pregnant.

Related Conditions & MeSH terms

• Atrial Flutter
• Atrial Premature Complexes
• Atrioventricular Block
• Bundle-Branch Block
• Indication for Peripheral Intravenous Catheterization
• Premature Atrial Contraction
• Premature Birth
• Premature Junctional Contraction
• Premature Ventricular Contraction
• Tachycardia
• Ventricular Premature Complexes

Intervention

Procedure:
• PICC placement with SHERLOCK 3CG™ Diamond TCS with MODUS II software
The SHERLOCK 3CG™ Diamond Tip Confirmation System (TCS) is an FDA-cleared fully-integrated magnetic tracking and ECG-based PICC tip confirmation technology, indicated for use as an alternative to chest x-ray and fluoroscopy for PICC tip placement confirmation in adult patients without any alterations of cardiac rhythms that change the normal presentation of the P-wave. A software package, MODUS II, has been developed to accurately analyze the entire ECG complex and identify the correct placement of the PICC tip based on a patient's individual ECG, in the absence of an easily identifiable P-wave. This software system is designed to provide visual and/or audio cues to notify the PICC placer of the location of the PICC tip relative to the cavoatrial junction (CAJ) of the patient.

Locations

Country	Name	City	State
Australia	Sunshine Coast University Hospital	Birtinya	Queensland
Australia	Fiona Stanley Hospital	Murdoch	Western Australia
United States	Cleveland Clinic	Cleveland	Ohio
United States	Moses Cone Hospital	Greensboro	North Carolina
United States	Vidant Medical Center	Greenville	North Carolina
United States	Summerlin Hospital and Medical Center	Las Vegas	Nevada
United States	J.W. Ruby Memorial Hospital	Morgantown	West Virginia
United States	Providence Sacred Heart Medical Center	Spokane	Washington

Sponsors (1)

Lead Sponsor	Collaborator
C. R. Bard

Countries where clinical trial is conducted

United States,  Australia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rate of successful PICC tip placement within the lower third of the superior vena cava (SVC) or in the cavoatrial junction (CAJ) using SLM2	Tip positioning is determined at bedside by the software via the Green Diamond Indicator (GDI+) and confirmed by CXR. PICC tip placement will be considered successful if it is determined to be in the lower 1/3 of the SVC or in the CAJ by an independent, blinded radiologist judging position retrospectively against pre-specified anatomical criteria.	The PICC insertion procedure is 60-90 mins in duration
Secondary	Rate of successful PICC tip placement within the lower third of the superior vena cava (SVC) or in the cavoatrial junction (CAJ) using SLM2 in the absence of a GDI	It is expected there will be some cases where the MODUS II software may fail to present a Green Diamond Indicator (GDI-). In the absence of a GDI, tip positioning is determined at bedside using magnetic tracking and external measurement per hospital protocol, with CXR required for tip confirmation. PICC tip placement will be considered successful if it is determined to be in the lower 1/3 of the SVC or in the CAJ by an independent, blinded radiologist judging position retrospectively against pre-specified anatomical criteria.	The PICC insertion procedure is 60-90 mins in duration
Secondary	Percent agreement between the site readings of the CXR (standard of care) versus those completed by an independent, blinded radiologist	An independent, blinded radiologist will judge PICC tip position retrospectively against pre-specified anatomical criteria compared with findings of the SLM2.	The PICC insertion procedure is 60-90 mins in duration